Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Growth in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 1,570,000 shares, a growth of 20.8% from the August 15th total of 1,300,000 shares. Based on an average trading volume of 19,150,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 7.1% of the company’s stock are short sold.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Armistice Capital LLC boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,770,000 shares of the company’s stock after acquiring an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned about 14.09% of Tonix Pharmaceuticals worth $1,519,000 as of its most recent SEC filing. Institutional investors and hedge funds own 82.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on TNXP shares. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Tuesday, September 10th. They issued a “sell” rating for the company. Alliance Global Partners upped their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

TNXP traded down $0.00 during mid-day trading on Monday, reaching $0.15. 3,054,850 shares of the company traded hands, compared to its average volume of 7,254,586. The stock has a market capitalization of $3.34 million, a P/E ratio of 0.00 and a beta of 2.09. Tonix Pharmaceuticals has a 52-week low of $0.13 and a 52-week high of $29.76. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. The company’s fifty day moving average price is $0.43 and its 200-day moving average price is $3.88.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Friday, August 16th. The company reported ($19.28) EPS for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The company had revenue of $2.21 million during the quarter, compared to the consensus estimate of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. On average, sell-side analysts expect that Tonix Pharmaceuticals will post -12.37 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.